Porphyria cutanea tarda and hepatitis C virus: a case-control study and meta-analysis of the literature
| Autor: | Tsu-Yi Chuang, Ryan Brashear, Charles Lewis |
|---|---|
| Rok vydání: | 1999 |
| Předmět: |
Male
Porphyria Cutanea Tarda medicine.medical_specialty Hepatitis C virus Population Blood Donors Dermatology medicine.disease_cause Seroepidemiologic Studies Internal medicine Epidemiology medicine Prevalence Humans Porphyria cutanea tarda education Retrospective Studies education.field_of_study business.industry Case-control study Australia Hepatitis C Antibodies medicine.disease Hepatitis C United States Surgery Europe Exact test Porphyria Case-Control Studies Female Viral disease business New Zealand |
| Zdroj: | Journal of the American Academy of Dermatology. 41(1) |
| ISSN: | 0190-9622 |
| Popis: | Background: Porphyria cutanea tarda (PCT) and hepatitis C virus (HCV) infection have been associated in several reports with the prevalence of HCV exhibiting considerable regional variation. However, most reports were confounded by selection bias and a regional prevalence of HCV in the populations studied. In the United States, only a few cases of this association have been reported to date. Objective: We conducted a study to evaluate the association between PCT and HCV in a US population. We used a case-control study design to control the systemic error that may occur during a selecting process or sampling procedure. Methods: We reviewed the medical records of Wishard Memorial Hospital, a county hospital serving metropolitan Indianapolis, Indiana, to perform a retrospective case-control study of 26 patients with PCT (as case) against 149,756 regional volunteer blood donors (as control-1) and 51 patients receiving methotrexate for psoriasis (as control-2). HCV antibody titers and other liver abnormalities were our main outcome measures. We then performed a weighted meta-analysis of 17 reports that had at least 17 patients in their study populations. Results: Sixteen (94%) of 17 PCT patients tested for HCV were antibody positive. Among blood donors, only 255 or 0.17% were HCV antibody positive ( P P = .0002, two-sided Fisher's exact test). For geographic comparison, meta-analysis of the literature demonstrated a varying regional prevalence of HCV in PCT patients as follows: Northern Europe 17%, Australia/New Zealand 20%, and Southern Europe 65%. Conclusion: Although a marked geographic variation was found in the worldwide prevalence of HCV in PCT patients, a very large percentage of US patients with PCT had HCV infection. Our results emphasize the need for clinicians to actively look for HCV in patients with PCT. (J Am Acad Dermatol 1999;41:31-6.) |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect